John A. Herrmann VP, General Counsel and Secretary Novavax, Inc. 240-268-2000 Novavax Acquires Isconova; Extended Public Tender Offer Period Closed Rockville, MD (

Novavax Acquires Isconova;

Extended Public Tender Offer Period Closed

Rockville, MD (August 22, 2013)-/GlobeNewswire, Inc. /-Novavax,

Inc. (Nasdaq: NVAX) announced today the number of shares tendered to it during the extended acceptance period for its recommended

public offer to acquire all issued and outstanding shares and warrants (warrants series 2005-I and 2005-II) of Isconova AB ("Isconova"),

which was first communicated on June 4, 2013, (the "Offer"), and which was extended to August 20, 2013.

As of July 30, 2013, approximately 12,152,077 shares and all

warrants issued by Isconova, corresponding to approximately 97.4 per cent of the shares and 100 per cent of the warrants issued

by Isconova, respectively, had been validly tendered and not properly withdrawn.

On July 31, 2013, Novavax declared the Offer unconditional and

completed the Offer in relation to securities tendered through July 30, 2013. Novavax also extended the acceptance period in the

Offer, which expired on 24:00, Central European Summer Time (6:00 pm Eastern Time) on August 20, 2013.

During the extended acceptance period, approximately 258,051

shares issued by Isconova, corresponding to approximately 2.1 per cent of the shares issued by Isconova, were validly tendered

and not properly withdrawn. Together with the 97.4 per cent of shares and 100 per cent of warrants tendered during the initial

acceptance period, approximately 99.5 per cent of the shares and 100 per cent of the warrants issued by Isconova were validly tendered

and not properly withdrawn during the Offer. Novavax will not make any additional extension of the acceptance period.

Settlement for shares tendered during the extended acceptance

period is expected to begin on or before August 27, 2013.

Novavax did not hold any shares or warrants in Isconova prior

to the announcement of the Offer and has not acquired any shares or warrants in Isconova outside the Offer.

Ropes & Gray LLP and Setterwalls Advokatbyr AB are

Novavax' legal advisors in conjunction with the offer. Pareto hman AB is Novavax' financial advisor in conjunction

Handelsbanken Capital Markets is Isconova's financial

advisor in conjunction with the Offer. Advokatfirman Lindahl KB is Isconova's legal advisors in conjunction with the Offer.

This information was made public on August 22, 2013, at 08:00

Novavax, Inc. (Nasdaq: NVAX) is a clinical-stage biopharmaceutical

company creating vaccines to address a broad range of infectious diseases worldwide. Using innovative recombinant nanoparticle

technology, as well as new and efficient manufacturing approaches, the company produces vaccine candidates to combat diseases,

with the goal of allowing countries to better prepare for and more effectively respond to rapidly spreading infections. Novavax

is committed to using its technology platform to create geographic-specific vaccine solutions and is therefore involved in several

international partnerships, including collaborations with Cadila Pharmaceuticals of India, LG Life Sciences of Korea and PATH.

Together, these organizations support Novavax' worldwide commercialization strategy and have the global reach to create real

and lasting change in the biopharmaceutical field. Additional information about Novavax is available on the company's website,